DNA pol δ cat Antibody (5G1): sc-53856

DNA pol δ cat Antibody (5G1) is a rat monoclonal IgG2a antibody that detects DNA pol δ in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). DNA pol δ plays a crucial role in DNA replication, recombination, and repair, which are essential processes for maintaining genome stability. DNA pol δ is particularly important for processing Okazaki fragments during DNA replication, as well as for excising damaged DNA and correcting mismatches during repair. Structurally, DNA pol δ consists of two main subunits: p125, which directly interacts with the sliding DNA clamp protein PCNA, and p50. The interaction between these subunits and PCNA enhances the processivity of DNA synthesis, allowing for efficient replication of the lagging strand. DNA pol δ is regulated by various cell cycle proteins, ensuring activity is tightly controlled during different phases of the cell cycle. Understanding DNA pol δ structure and function is essential for elucidating DNA replication and repair mechanisms, and for developing potential therapeutic strategies targeting these processes in diseases such as cancer.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DNA pol δ cat Antibody (5G1) References:

1. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.  |  Valle, L., et al. 2014. Hum Mol Genet. 23: 3506-12. PMID: 24501277
2. Elevated expression of POLD1 is associated with poor prognosis in breast cancer.  |  Qin, Q., et al. 2018. Oncol Lett. 16: 5591-5598. PMID: 30344713
3. The POLD1R689W variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors.  |  Job, A., et al. 2020. Sci Rep. 10: 18924. PMID: 33144657
4. Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor.  |  He, J., et al. 2021. Ann Transl Med. 9: 129. PMID: 33569431
5. DNA Polymerase Delta 1 Catalytic Subunit (POLD1) as a Prognostic Factor in Clear Cell Renal Cell Carcinoma Patients.  |  Godlewski, J., et al. 2022. In Vivo. 36: 1188-1194. PMID: 35478106
6. Unraveling the impact of a germline heterozygous POLD1 frameshift variant in serrated polyposis syndrome.  |  Bonjoch, L., et al. 2023. Front Mol Biosci. 10: 1119900. PMID: 36756361
7. Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.  |  Zheng, S., et al. 2023. Thorac Cancer. 14: 2269-2274. PMID: 37345618
8. POLD1 DEDD Motif Mutation Confers Hypermutation in Endometrial Cancer and Durable Response to Pembrolizumab.  |  Wei, CH., et al. 2023. Cancers (Basel). 15: PMID: 38067377
9. Discovery of recessive effect of human polymerase δ proofreading deficiency through mutational analysis of POLD1-mutated normal and cancer cells.  |  Andrianova, MA., et al. 2024. Eur J Hum Genet. 32: 837-845. PMID: 38658779
10. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.  |  Mosalem, O., et al. 2024. Oncologist. 29: e1224-e1227. PMID: 38776551

The preferred DNA pol δ cat antibody is DNA pol δ cat Antibody (A-9): sc-17776.